On Jan. 11, 2018, FDA announced safety labeling changes to prescription opioid cough and cold medicines containing codeine or hydrocodone to limit the use of products in children younger than 18 years old. According to the agency, these changes are being made in response to the risks associatedOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.